This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Anti-Integrin Therapies in IBD: New Data for Your Crohn's Disease Patients

Anti-Integrin Therapies in IBD: New Data for Your Crohn's Disease Patients

Format

Patient Case Study

Time to Complete

30 minutes

Released

March 15, 2017

Expires

March 15, 2018
Add to Queue


Maximum Credits

0.50 / AMA PRA Category 1 CreditTM
0.50 / CE for Nurses (0.50 hours of pharmacology)

Accredited Provider

Jointly provided by American Academy of CME, Inc. and Spire Learning

Commercial Supporter

Supported by an educational grant provided by Takeda Pharmaceuticals U.S.A., Inc.

Program Description

Based on a satellite symposium held at the 2016 Advances in Inflammatory Bowel Diseases Crohn’s & Colitis Foundation of America’s Clinical & Research Conference.

This case-based activity will:

  • Explore management options in a patient with Crohn’s disease who has concerns about adverse effects associated with potential treatment options
  • Demonstrate how to use clinical trial results and real-world data for anti-integrin agents in your patient treatment decisions
  • Provide updates on emerging anti-integrin therapies that are currently under investigation for IBD management

Intended Audience

This activity has been designed to meet the educational needs of gastroenterologists, internal medicine specialists, physicians-in-training, advanced practice nurses, physician assistants, nurses, and other healthcare professionals who are involved and/or interested in the therapeutic management of patients with inflammatory bowel disease (IBD).

Learning Outcomes/Objectives

At the conclusion of this educational activity, participants should be better able to:

  • Evaluate efficacy and safety data from clinical trials investigating anti-integrin therapies for IBD management
  • Incorporate findings from real-world data for anti-integrin agents into management decisions for patients with IBD
  • Summarize the mechanism of action, efficacy, and safety of emerging anti-integrin agents for IBD treatment

Conflict Of Interest Disclosure Policy

According to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant relationships with any commercial interests related to this activity. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation. All educational materials are reviewed for fair balance, scientific objectivity, and levels of evidence. Disclosures are as follows:

Faculty

Asher Kornbluth, MD
Clinical Professor of Medicine
Mount Sinai Medical Center and the
Icahn School of Medicine at Mount Sinai
New York, NY

Dr. Kornbluth discloses the following:
Consultant/Advisory/Scientific Advisory Board: AbbVie; Janssen; Millennium/Takeda Pharmaceuticals; Prometheus
Clinical Trials: AbbVie; Bristol-Myers Squibb; Janssen
Speaker’s Bureau: AbbVie; Janssen; Millennium/Takeda Pharmaceuticals; Prometheus; Santarus/Salix

Accredited Provider Disclosures

American Academy of CME, Inc.
John JD Juchniewicz, MCIS, CHCP, discloses the following:
No relevant financial relationships with any commercial interests.

Natalie Kirkwood, RN, BSN, JD, (Lead Nurse Planner) discloses the following:
No relevant financial relationships with any commercial interests.

Independent Reviewer
Ashley A. Bochenek, MSN, FNP-BC (Reviewer)

Nurse Practitioner – Gastrotenterology (Inflammatory Bowel Disease)
University of Chicago Medical Center

Ms. Bochenek discloses the following:
Speaker’s Bureau: AbbVie; Janssen

Spire Learning
Lisa Conklin discloses the following:
No relevant financial relationships with any commercial interests.

Elysa Ripa discloses the following:
No relevant financial relationships with any commercial interests.

Jaime Symowicz, PhD, discloses the following:
No relevant financial relationships with any commercial interests.

Credit

0.50

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of American Academy of CME, Inc., (Academy) and Spire Learning. American Academy of CME, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

Designation Statement

American Academy of CME, Inc. designates this enduring material for a maximum of 0.50 AMA PRA Category 1 CreditTM . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit

0.50

Type

CE for Nurses

Accreditation Statement

American Academy of CME, Inc., is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).

Designation Statement

American Academy of CME, Inc., designates this activity for 0.50 contact hours. (0.50 pharmacotherapeutic contact hours).

Disclosure of Unlabeled Use

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the FDA, specifically the use of etrolizumab and PF-00547659 for the treatment of inflammatory bowel disease. Faculty have been asked to indicate such discussion at the time of their mention. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Levels of Evidence

Levels of evidence are provided for any patient care recommendations made during this presentation.

  • Level A (randomized controlled trial/meta-analysis): High-quality randomized controlled trial (RCT) that considers all important outcomes. High-quality meta-analysis (quantitative systematic review) using comprehensive search strategies.
  • Level B (other evidence): A well-designed, nonrandomized clinical trial. A nonquantitative systematic review with appropriate search strategies and well-substantiated conclusions. Includes lower quality RCTs, clinical cohort studies and case-controlled studies with nonbiased selection of study participants and consistent findings. Other evidence, such as high-quality, historical, uncontrolled studies, or well-designed epidemiological studies with compelling findings, is also included.
  • Level C (consensus/expert opinion): Consensus viewpoint or expert opinion.
Each rating is applied to a single reference in the lecture/article, not to the entire body of evidence on a topic.

Disclaimer

The opinions expressed in this educational activity are those of the faculty, and do not represent those of Academy, Spire Learning, or American Nurses Credentialing Center’s Commission on Accreditation. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.

For any questions, please contact: CEServices@academycme.org.

Instructions

To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.

SYSTEM REQUIREMENTS

Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue


Related to this activity